Reproxalap Ophthalmic Solution (0.25%) QID
ADX-102-DED-012
Phase 3 small_molecule completed
Quick answer
Reproxalap Ophthalmic Solution (0.25%) QID for Dry Eye is a Phase 3 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Dry Eye
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed